Best GLP-1 Providers in Massachusetts (2026)

See by medication

Looking for a specific GLP-1? Browse Massachusetts providers by drug.

About GLP-1s in Massachusetts

Massachusetts has progressive telehealth laws supporting GLP-1 prescribing. MassHealth (Medicaid) covers GLP-1s for both diabetes and obesity with prior authorization.

• •Massachusetts's adult obesity rate is 27.2%, among the lowest in the US
• •MassHealth covers GLP-1s for obesity with prior authorization
• •Boston is a major hub for telehealth medicine and innovation

Top Cities for GLP-1 Treatment in Massachusetts

Telehealth providers ship to all Massachusetts addresses, but demand is highest in these metro areas:

Prefer an in-person clinic? Browse the Massachusetts GLP-1 clinic directory →

GLP-1 Care Access in Massachusetts: The Numbers

Massachusetts has 845 NPI-registered in-person weight-management clinics across 124 cities — 17 with an obesity-medicine taxonomy, 594 endocrinology, and 251 bariatric — alongside 94 telehealth programs that ship to Massachusetts addresses. The cheapest verified ongoing compounded semaglutide price available to Massachusetts residents is $79/mo (tirzepatide: $97/mo). Full methodology and the 50-state table: GLP-1 care access by state.

Insurance & Medicaid in Massachusetts

In Q1 2026, Massachusetts Medicaid reimbursed approximately $121,171,872 across 116,367 GLP-1 prescriptions (all covered indications, gross before rebates — federal SDUD data; full state series here).

Most insurance plans in Massachusetts cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro), but coverage for obesity-only indications (Wegovy, Zepbound) is much more limited and often requires prior authorization. If your insurance won't cover brand-name GLP-1s, compounded semaglutide through telehealth is typically the most affordable option at around $229/mo.

For the exact criteria, drug list, and appeal process, read our Massachusetts Medicaid GLP-1 coverage & prior-authorization guide. For coverage backdoors, Zepbound is FDA-approved for obstructive sleep apnea, and Wegovy for kidney and cardiovascular indications, which some plans cover even when they exclude weight-loss-only use.

Obesity in Massachusetts

According to CDC data, 27.2% of Massachusetts adults have obesity (BMI of 30 or higher). This places Massachusetts at #47 out of 50 states. Access to GLP-1 medications like semaglutide and tirzepatide has expanded significantly through telehealth, helping Massachusetts residents get clinically supervised weight loss treatment from home.

To choose a medication, compare the clinical-trial results behind each drug, see our best semaglutide and tirzepatide provider rankings, or track the next-generation GLP-1 pipeline.

Frequently Asked Questions